Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Form 8.3 - [CRANEWARE PLC - 30 05 2025] - (CGWL)
-
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
-
Signify share repurchase period update
-
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance
-
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
-
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
-
Dynacor Group Declares June 2025 Dividend
-
USW welcomes federal commitment to Canadian steel and aluminum in national infrastructure and defence projects
-
Asante Receives Second US$100 Million Advance From Fujairah, Provides Interim Financing Update
-
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
-
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
-
Sanofi Exercises License Extension Option to Nurix’s STAT6 Program
-
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
-
Nokia and Andorix partner to accelerate Private 5G and Edge solutions in North American real estate market
-
Marex Group plc to Participate in Upcoming Piper Sandler Global Exchange & Trading Conference
-
Highwoods Provides Leasing Update
-
Rocky Shore Announces the Sale of its Hemlo-Area Claims
-
Helium Evolution Closes Second Tranche of Expanded Private Placement
-
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
-
Big Names & Fresh Faces Headline Rogers Sports & Media’s Canadian Originals Slate for HGTV and Food Network
-
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic
-
Plum Wins Gold at the 5th Annual 2025 Globee® Awards for Disruptors
-
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
-
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
-
Coda Octopus Group Sets Fiscal Second Quarter 2025 Earnings Conference Call for Monday, June 16, 2025, at 10 a.m. Eastern Time
-
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo’s Arguments and Director Slate
-
Aura Minerals Agrees to Acquire the Mineração Serra Grande Gold Mine in Goiás, Brazil
-
ConnectOne Bancorp, Inc. Completes Merger With the First of Long Island Corporation
-
Vanguard Food LP Announces Closing of Transaction to Create Emerging Leader in North American Produce Industry
-
Village Farms International Announces Closing of Transaction to Privatize its Fresh Produce Business
-
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
-
Nokia and Andorix partner to accelerate Private 5G and Edge Solutions in North American real estate market
-
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
-
Denodo University Challenge Now Open: Data and AI for Real-World Impact
-
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
-
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
-
CW Petroleum Corp (OTCQB: CWPE) Shareholder Update 6/2/2025
-
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
-
ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare workforce shortage
-
Marex Group plc to Participate in Upcoming Piper Sandler Global Exchange & Trading Conference
-
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
-
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
-
SAIC Announces First Quarter of Fiscal Year 2026 Results
-
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
-
Net Asset Value(s)
-
Patagonia Gold Announces Completion of US$40 Million Investment Into Its Calcatreu Project
-
Codere Online Announces Filing of 2024 Annual Report on Form 20-F
-
Castellum, Inc. to Participate in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow” Virtual Conference Presented by Maxim Group LLC on Tuesday, June 3rd – Thursday,
-
Brazil Potash Year to Date Summary: Company Achieves Milestones, Advancing Strategic Autazes Project Further Towards Construction
-
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
